Requirement for p38 mitogen-activated protein kinase activity in neointima formation after vascular injury

Circulation

Volumn 118, Issue 6, 2008, Pages 658-666

  Proctor, Brandon M ^a,b   Jin, Xiaohua ^a,b   Lupu, Traian S ^a,b   Muglia, Louis J ^b   Semenkovich, Clay F ^c   Muslin, Anthony J ^a,b,d  

^a Center for Cardiovascular Research   (United States)

^b Washington University   (United States)

^c WASHINGTON UNIVERSITY   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; DOXYCYCLINE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; PLATELET DERIVED GROWTH FACTOR; RETINOBLASTOMA PROTEIN; SMALL INTERFERING RNA; CELL CYCLE PROTEIN; MCM6 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD VESSEL INJURY; CAROTID ARTERY INJURY; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DNA REPLICATION; EMBRYO; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; MINICHROMOSOME; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SMOOTH MUSCLE FIBER; TRANSGENIC MOUSE; ANGIOPLASTY; ANIMAL; C57BL MOUSE; CELL DIVISION; ENZYMOLOGY; FEMALE; GENETICS; INJURY; INTIMA; MALE; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE;

ANGIOPLASTY; ANIMALS; CAROTID ARTERY INJURIES; CELL CYCLE PROTEINS; CELL DIVISION; FEMALE; GENE EXPRESSION; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUSCLE, SMOOTH, VASCULAR; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; RETINOBLASTOMA PROTEIN; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUNICA INTIMA;

EID: 50349083898     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.107.734848     Document Type: Article

References (27)

1. Pauletto P, Puato M, Faggin E, Santipolo N, Pagliara V, Zoleo M, Deriu GP, Grego F, Plebani M, Sartore S, Bon GB, Heymes C, Samuel JL, Pessina AC. Specific cellular features of atheroma associated with development of neointima after carotid endarterectomy: the Carotid Atherosclerosis and Restenosis Study. Circulation. 2000;102:771-778.
2. Orford JL, Selwyn AP, Ganz P, Popma JJ, Rogers C. The comparative pathobiology of atherosclerosis and restenosis. Am J Cardiol. 2000; 86(suppl):6H-11H.
3. Lindner V, Reidy MA. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci U S A. 1991;88:3739-3743.
4. Crowley ST, Ray CJ, Nawaz D, Majack RA, Horwitz LD. Multiple growth factors are released from mechanically injured vascular smooth muscle cells. Am J Physiol. 1995;269(pt 2):H1641-H1647.
5. Wilcox JN. Molecular biology: insight into the causes and prevention of restenosis after arterial intervention. Am J Cardiol. 1995;72:88E-95E.
6. Zhang S, Ren J, Khan MF, Cheng AM, Abendschein D, Muslin AJ. Grb2 is required for the development of neointima in response to vascular injury. Arterioscler Thromb Vasc Biol. 2003;23:1788-1793.
7. Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev. 2004;68:320-344.
8. Engel FB, Schebesta M, Duong MT, Lu G, Ren S, Madwed JB, Jiang H, Wang Y, Keating MT. p38 MAP kinase inhibition enables proliferation of adult mammalian cardiomyocytes. Genes Dev. 2005;19:1175-1187.
9. Li M, Georgakopoulos D, Lu G, Hester L, Kass DA, Hasday J, Wang Y. p38 MAP kinase mediates inflammatory cytokine induction in cardiomyocytes and extracellular matrix remodeling in heart. Circulation. 2005;111:2494-2502.
10. Pedraza-Alva G, Koulnis M, Charland C, Thornton T, Clements JL, Schlissel MS, Rincon M. Activation of p38 MAP kinase by DNA double-strand breaks in V(D)J recombination induces a G2/M cell cycle checkpoint. EMBO J. 2006;25:763-773.
11. Chen S, Qiong Y, Gardner DG. A role for p38 mitogen-activated protein kinase and c-myc in endothelin-dependent rat aortic smooth muscle cell proliferation. Hypertension. 2006;47:252-258.
12. Jacob T, Ascher E, Alapat D, Olevskaia Y, Hingorani A. Activation of p38 MAPK signaling cascade in a VSMC injury model: role of p38 MAPK inhibitors in limiting VSMC proliferation. Eur J Endovasc Surg. 2005;29: 470-478.
13. Kavurma MM, Khachigian LM. ERK, JNK, and p38 MAP kinases differentially regulate proliferation and migration of phenotypically distinct smooth muscle cell subtypes. J Cell Biochem. 2003;89:289-300.
14. Bernal-Mizrachi C, Gates AC, Weng S, Imamura T, Knutsen RH, DeSantis P, Coleman T, Townsend RR, Muglia LJ, Semenkovich CF. Vascular respiratory uncoupling increases blood pressure and atherosclerosis. Nature. 2005; 435:502-506.
15. Xing H, Zhang S, Weinheimer C, Kovacs A, Muslin AJ. 14-3-3 Proteins inhibit apoptosis and differentially regulate MAPK cascades. EMBO J. 2000; 19:349-358.
16. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell. 1995; 81:323-330.
17. La Thangue NB. E2F and the molecular mechanisms of early cell-cycle control. Biochem Soc Trans. 1996;24:54-59.
18. Nevins JR. E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science. 1992;258:424-429.
19. Marra DE, Simoncini T, Liao JK. Inhibition of vascular smooth muscle cell proliferation by sodium salicylate mediated by upregulation of p21(Waf1) and p27(Kip1). Circulation. 2000;102:2124-2130.
20. You Z, Komamura Y, Ishimi Y. Biochemical analysis of the intrinsic Mcm4-Mcm6-mcm7 DNA helicase activity. Mol Cell Biol. 1999;19:8003-8015.
21. Blaschke E, Leppanen O, Takata Y, Caglayan E, Liu J, Fishbein MC, Kappert K, Nakayama KI, Collins AR, Fleck E, Hsueh WA, Law RE, Bruemmer D. Liver X receptor agonists suppress vascular smooth muscle cell proliferation and inhibit neointima formation in balloon-injured rat carotid arteries. Circ Res. 2004;95:e110-e123.
22. Zhang S, Weinheimer C, Courtois M, Kovacs A, Zhang CE, Cheng AM, Wang Y, Muslin AJ. The role of the Grb2-p38 MAPK signaling pathway in cardiac hypertrophy and fibrosis. J Clin Invest. 2003;111:833-841.
23. Braz JC, Bueno OF, Liang Q, Wilkins BJ, Dai YS, Parsons S, Braunwart J, Glascock BJ, Klevitsky R, Kimball TF, Hewett TE, Molkentin JD. Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling. J Clin Invest. 2003;111: 1475-1486.
24. Ren J, Zhang S, Kovacs A, Wang Y, Muslin AJ. Role of p38alpha MAPK in cardiac apoptosis and remodeling after myocardial infarction. J Mol Cell Cardiol. 2005;38:617-623.
25. See F, Thomas W, Way K, Tzanidis A, Kompa A, Lewis D, Itescu S, Krum H. p38 Mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat. J Am Coll Cardiol. 2004;44:1679-1689.
26. Li M, Georgakopoulos D, Lu G, Hester L, Kass DA, Hasday J, Wang Y. p38 MAP kinase mediates inflammatory cytokine induction in cardiomyocytes and extracellular matrix remodeling in heart. Circulation. 2005;111: 2494-2502.
27. Kerkela R, Force T. p38 mitogen-activated protein kinase: a future target for heart failure therapy? J Am Coll Cardiol. 2006;48:556-558.